Literature DB >> 32651324

Increased Contact System Activation in Mild Cognitive Impairment Patients with Impaired Short-Term Memory.

Pradeep K Singh1, Zu-Lin Chen1, Sidney Strickland1, Erin H Norris1.   

Abstract

An activated plasma contact system is an abnormality observed in many Alzheimer's disease (AD) patients. Since mild cognitive impairment (MCI) patients often develop AD, we analyzed the status of contact system activation in MCI patients. We found that kallikrein activity, high molecular weight kininogen cleavage, and bradykinin levels- measures of contact system activation- were significantly elevated in MCI patient plasma compared to plasma from age- and education-matched healthy individuals. Changes were more pronounced in MCI patients with impaired short-term recall memory, indicating the possible role of the contact system in early cognitive changes.

Entities:  

Keywords:  Alzheimer’s disease; bradykinin; contact activation; high molecular weight zzm321990kininogen; memory impairment; mild cognitive impairment; plasma kallikrein

Year:  2020        PMID: 32651324      PMCID: PMC7587041          DOI: 10.3233/JAD-200343

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  48 in total

Review 1.  Contact system revisited: an interface between inflammation, coagulation, and innate immunity.

Authors:  A T Long; E Kenne; R Jung; T A Fuchs; T Renné
Journal:  J Thromb Haemost       Date:  2016-02-09       Impact factor: 5.824

Review 2.  Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics.

Authors:  Dennis J Selkoe; Dale Schenk
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002-01-10       Impact factor: 13.820

3.  Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss.

Authors:  Michelle M Mielke; Norman J Haughey; Veera Venkata Ratnam Bandaru; Steven Schech; Richard Carrick; Michelle C Carlson; Susumu Mori; Michael I Miller; Can Ceritoglu; Timothy Brown; Marilyn Albert; Constantine G Lyketsos
Journal:  Alzheimers Dement       Date:  2010-09       Impact factor: 21.566

4.  Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice.

Authors:  Anna K Kopec; Nikita Joshi; Keara L Towery; Karen M Kassel; Bradley P Sullivan; Matthew J Flick; James P Luyendyk
Journal:  J Pharmacol Exp Ther       Date:  2014-08-19       Impact factor: 4.030

5.  Rates of progression in mild cognitive impairment and early Alzheimer's disease.

Authors:  Martha Storandt; Elizabeth A Grant; J Philip Miller; John C Morris
Journal:  Neurology       Date:  2002-10-08       Impact factor: 9.910

6.  Biochemical and structural analysis of the interaction between β-amyloid and fibrinogen.

Authors:  Daria Zamolodchikov; Hanna E Berk-Rauch; Deena A Oren; Daniel S Stor; Pradeep K Singh; Masanori Kawasaki; Kazuyoshi Aso; Sidney Strickland; Hyung Jin Ahn
Journal:  Blood       Date:  2016-07-07       Impact factor: 22.113

7.  Injection of bradykinin or cyclosporine A to hippocampus induces Alzheimer-like phosphorylation of Tau and abnormal behavior in rats.

Authors:  Quanbao Wang; Jianzhi Wang
Journal:  Chin Med J (Engl)       Date:  2002-06       Impact factor: 2.628

8.  Zinc-dependent activation of the plasma kinin-forming cascade by aggregated beta amyloid protein.

Authors:  Y Shibayama; K Joseph; Y Nakazawa; B Ghebreihiwet; E I Peerschke; A P Kaplan
Journal:  Clin Immunol       Date:  1999-01       Impact factor: 3.969

9.  The cortical topography of temporal lobe hypometabolism in early Alzheimer's disease.

Authors:  W J Jagust; J L Eberling; B C Richardson; B R Reed; M G Baker; T E Nordahl; T F Budinger
Journal:  Brain Res       Date:  1993-12-03       Impact factor: 3.252

Review 10.  Plasma biomarkers for mild cognitive impairment and Alzheimer's disease.

Authors:  Fei Song; Anne Poljak; George A Smythe; Perminder Sachdev
Journal:  Brain Res Rev       Date:  2009-05-21
View more
  5 in total

1.  The contact activation system and vascular factors as alternative targets for Alzheimer's disease therapy.

Authors:  Pradeep K Singh; Ana Badimon; Zu-Lin Chen; Sidney Strickland; Erin H Norris
Journal:  Res Pract Thromb Haemost       Date:  2021-05-03

2.  Plasma contact factors as novel biomarkers for diagnosing Alzheimer's disease.

Authors:  Jung Eun Park; Do Sung Lim; Yeong Hee Cho; Kyu Yeong Choi; Jang Jae Lee; Byeong C Kim; Kun Ho Lee; Jung Sup Lee
Journal:  Biomark Res       Date:  2021-01-09

3.  A modular map of Bradykinin-mediated inflammatory signaling network.

Authors:  D A B Rex; K Deepak; Neelanchal Vaid; Shobha Dagamajalu; Richard Kumaran Kandasamy; Trude Helen Flo; T S Keshava Prasad
Journal:  J Cell Commun Signal       Date:  2021-10-29       Impact factor: 5.782

Review 4.  Direct Oral Anticoagulants (DOACs) for Therapeutic Targeting of Thrombin, a Key Mediator of Cerebrovascular and Neuronal Dysfunction in Alzheimer's Disease.

Authors:  Klaus Grossmann
Journal:  Biomedicines       Date:  2022-08-04

5.  Blocking domain 6 of high molecular weight kininogen to understand intrinsic clotting mechanisms.

Authors:  Pradeep K Singh; Zu-Lin Chen; Katharina Horn; Erin H Norris
Journal:  Res Pract Thromb Haemost       Date:  2022-10-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.